We’re well aware of the persistent challenges in glucose monitoring within the CGM market, impacting the overall diabetes management experience. The quest for precision and reliability in readings has been an ongoing challenge, especially concerning the seamless integration of automatic insulin delivery.

Despite significant strides in the CGM market, accuracy and reliability of glucose readings remain crucial for effective diabetes management.

Various companies are tackling this challenge through different avenues. Some refine sensing technologies, while others enhance data processing algorithms. However, we’re excited to spotlight an innovation that’s breaking new ground in this arena – Medtronic Minimed.

The Innovation: Orthogonally Redundant Glucose Sensor:

Medtronic’s game-changing orthogonally redundant glucose sensor integrates two distinct sensing technologies into a single device. By combining optical and non-optical (electrochemical) methods, it delivers two independent readings – like having two reliable witnesses corroborating the data. This dual-sensor marvel aligns perfectly with the latest advancements in CGM technology, especially supporting automatic insulin infusion pumps for a more refined approach to diabetes management.

Why It’s a Game-Changer:

Dual-Sensor Precision: Two independent readings provide an unparalleled level of accuracy, ensuring a more reliable foundation for diabetes management.

Innovation in Integration: This breakthrough supports automatic insulin infusion pumps, marking a significant advancement in the seamless integration of CGM and insulin delivery.